Intra-Cellular Therapies (NASDAQ:ITCI) Hits New 1-Year High – Should You Buy?

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) reached a new 52-week high during trading on Monday . The stock traded as high as $131.40 and last traded at $131.30, with a volume of 1500320 shares traded. The stock had previously closed at $131.36.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on ITCI shares. Leerink Partnrs downgraded Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $132.00 price objective (up from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday, January 22nd. Baird R W downgraded Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Cantor Fitzgerald upgraded Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 14th. Finally, Piper Sandler restated a “neutral” rating and set a $132.00 price target (up from $107.00) on shares of Intra-Cellular Therapies in a research note on Tuesday, January 14th. Ten equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Intra-Cellular Therapies currently has an average rating of “Hold” and a consensus price target of $106.08.

Intra-Cellular Therapies Stock Performance

The stock has a market capitalization of $13.98 billion, a PE ratio of -151.09 and a beta of 0.69. The stock has a 50-day moving average price of $125.91 and a two-hundred day moving average price of $96.52.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The company had revenue of $199.22 million for the quarter, compared to analysts’ expectations of $205.08 million. As a group, equities analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Accredited Wealth Management LLC purchased a new position in shares of Intra-Cellular Therapies during the 4th quarter valued at about $28,000. True Wealth Design LLC purchased a new position in Intra-Cellular Therapies in the 3rd quarter worth approximately $32,000. GAMMA Investing LLC lifted its holdings in Intra-Cellular Therapies by 46.3% in the 4th quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 240 shares in the last quarter. Venturi Wealth Management LLC purchased a new position in Intra-Cellular Therapies in the 4th quarter worth approximately $96,000. Finally, Wilmington Savings Fund Society FSB purchased a new position in Intra-Cellular Therapies in the 3rd quarter worth approximately $97,000. 92.33% of the stock is owned by hedge funds and other institutional investors.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.